Articles

13 May 2015

BIONANOPARTICLES: A GREEN NANOCHEMICAL APPROACH

{ DOWNLOAD AS PDF }

28 April 2015

A REVIEW: ANTI-DIABETIC ACTIVITY OF HERBAL DRUGS

{ DOWNLOAD AS PDF }

28 April 2015

A SIMPLE SPECTROPHOTOMETRIC ESTIMATION OF CEFTRIAXONE SODIUM IN BULK AND STERILE FORMULATION

{ DOWNLOAD AS PDF }

26 April 2015

MIDDLE EAST RESPIRATORY SYNDROME CORONAVIRUS: AN EMERGING INFECTION

{ DOWNLOAD AS PDF }

ABOUT AUTHORS:
Suresh Rewar¹*, Dashrath Mirdha², Prahlad Rewar³
¹Department of pharmaceutics, Rajasthan University of Health Sciences, Jaipur, Rajasthan,
²Dr. Sarvepali Radhakrishnan Rajasthan Ayurved University, Jodhpur, Rajasthan, India
³Jawaharlal Nehru Medical College, Ajmer, Rajasthan, India
sureshrewar1990@gmail.com

ABSTRACT
A severe viral illness caused by a newly discovered coronavirus was first reported in the Middle East in 2012. The virus has since been named the Middle East respiratory syndrome coronavirus (MERS-CoV). MERS-CoV cases have been reported in several countries around the world in travelers from the Middle East., A substantial number of Indians live and work in Gulf countries. People from India also travel to Saudi Arabia as Pilgrims to Hajj. The illness has a high mortality rate. Limited human-to-human transmission has occurred including transmission to health care workers. The source of the virus remains unclear, but camels are a possible source. Since April 2012 and as of 20 February 2015, 1042 cases (including 419 deaths) of Middle East respiratory syndrome coronavirus (MERS-CoV) have been reported by local health authorities worldwide. Laboratory confirmation of MERS-CoV infections to date has largely been by real-time reverse transcription polymerase chain reaction (rRT-PCR) of lower respiratory tract specimens. Neither a vaccine nor effective therapy against the virus is available. Treatment consists of limited to supportive care, including mechanical ventilation for respiratory failure and/or hemodialysis in the setting of renal failure. Therapeutic modalities based on monoclonal antibodies (mAbs) have shown clinical success in the treatment of many diseases.

25 April 2015

Rapidly Changing Equations in Topical Pain Management Market

Editorial, Apr 2015 issue

“ Why this particular segment of FMCG or OTC will surge, can be understood from the fact that people want immediate relief from pain, come what may, and this lead to makeover of traditional wide mouth bottle into ointment or spray type of container or dosage form

24 April 2015

MIDDLE EAST RESPIRATORY SYNDROME CORONAVIRUS: AN EMERGING INFECTION

ABOUT AUTHORS:
Suresh Rewar¹*, Dashrath Mirdha², Prahlad Rewar³
¹Department of pharmaceutics, Rajasthan University of Health Sciences, Jaipur, Rajasthan,
²Dr. Sarvepali Radhakrishnan Rajasthan Ayurved University, Jodhpur, Rajasthan, India
³Jawaharlal Nehru Medical College, Ajmer, Rajasthan, India
sureshrewar1990@gmail.com

ABSTRACT
A severe viral illness caused by a newly discovered coronavirus was first reported in the Middle East in 2012. The virus has since been named the Middle East respiratory syndrome coronavirus (MERS-CoV). MERS-CoV cases have been reported in several countries around the world in travelers from the Middle East., A substantial number of Indians live and work in Gulf countries. People from India also travel to Saudi Arabia as Pilgrims to Hajj. The illness has a high mortality rate. Limited human-to-human transmission has occurred including transmission to health care workers. The source of the virus remains unclear, but camels are a possible source. Since April 2012 and as of 20 February 2015, 1042 cases (including 419 deaths) of Middle East respiratory syndrome coronavirus (MERS-CoV) have been reported by local health authorities worldwide. Laboratory confirmation of MERS-CoV infections to date has largely been by real-time reverse transcription polymerase chain reaction (rRT-PCR) of lower respiratory tract specimens. Neither a vaccine nor effective therapy against the virus is available. Treatment consists of limited to supportive care, including mechanical ventilation for respiratory failure and/or hemodialysis in the setting of renal failure. Therapeutic modalities based on monoclonal antibodies (mAbs) have shown clinical success in the treatment of many diseases.

15 April 2015

MENs COSMETICS

ABOUT AUTHOR:
Vinay Kumar Singh
General Manager-Technical,
Mikasa Cosmetics Limited,
Ahmedabad, Gujarat
vinay.s@mikasacosmetics.com

Isn’t ironical to call a cosmetics, MEN’S Cosmetics. Cosmetics are substance that enhance beauty of a person, protects from harmful environment, cleanses, hides blemishes, makes one attractive and ultimately boosts the confidence. Thus Cosmetics per say do not differentiate between users, but humans do.

14 April 2015

MEDICAL USES OF RADIOPHARMACEUTICALS

{ DOWNLOAD AS PDF }

ABOUT AUTHORS:
Mohammad Akbar Dar, Mubashir Hussain Masoodi*, Saeema Farooq
Dept. of Pharmaceutical Sciences,
Faculty of Applied Sciences, University of Kashmir, Srinagar, J&K, India
akbardr297@gmail.com

ABSTRACT
A radiopharmaceutical is a preparation intended for in-vivo use that contains a radionuclide in the form of a simple salt or a complex. It may exist as a solid, liquid, gas or a pseudo gas. The chemical and physical identity and a form of a radiopharmaceutical are very important because in each case, once administered the radiopharmaceutical is intended to target certain tissues, binding sites, biochemical pathways. A radiopharmaceutical can be used for either diagnostic or therapeutic purposes depending on its specific physicochemical and radiation properties. The characteristic of radioactive decay is what makes radioisotopes useful in their medical applications; however, different applications will take advantage of radioactive emissions in different ways. Radioactive materials are regularly used to treat medical conditions, diagnosis pathology, visualize and measure physiological functions, and localize structures and pathways. This review describes both the therapeutic as well as diagnostic uses of radiopharmaceuticals.

[adsense:336x280:8701650588]

13 April 2015

NANOPARTICLE (NP) AS A TARGETING DRUG DELIVERY SYSTEM TO BLOOD-BRAIN BARRIER (BBB): A REVIEW

{ DOWNLOAD AS PDF }

ABOUT AUTHROS:
Bikash Debnath*, Md. JashimUddin, Debasish Maiti
State Biotech Hub, Department of Human Physiology,
Tripura University, Suryamaninagar.
*bikashrips2014@gmail.com

ABSTRACT:
Central nervous system (CNS) drug development will be biology driven. Due to absence of functional platform for CNS drug targeting since, the large molecules pharmaceuticals cannot be delivered to brain. About 1.5 billion people worldwide are suffering from various type of central nervous system (CNS) disorders. Overcome to this problem modern pharmaceutical technology manufacturing the nonaparticles. Properly use of nonamedicines (nanoparticles) is one of the ways to control the CNS disorder in all over world. Nanoparticles are particles between 1 to 100 nm in size. Using nanotechnology it is possible to deliver the drug to the specific site of the tissue across the Blood -Brain Barrier (BBB).Various types of nanoparticle are available for treatment of CNS disorders. These are lipid based nanoparticles, solid lipid nanoparticles, polymer-based nanoparticles etc.

10 April 2015

ESTIMATION OF ONDANSETRON HYDROCHLORIDE IN BULK AND FORMULATION BY SECOND ORDER DERIVATIVE AREA UNDER CURVE UV-SPECTROPHOTOMETRIC METHODS

{ DOWNLOAD AS PDF }